The Daily Toke

April 20, 2026

# THC & Politics: A Shifting Landscape on 4/20

President Donald Trump signed an executive order accelerating access to psychedelic treatments for mental health conditions while simultaneously pressuring the Department of Justice to speed up marijuana rescheduling—a move he complained was being "slow-walked" four months after issuing his initial directive. The psychedelics order directs the FDA to provide expedited review through a National Priority Voucher program promising one- to two-month timelines, and allows patients to access investigational psychedelics through the federal Right To Try Act. 🚀 THIS IS COOL The shift is remarkable enough that when Trump joked "Can I have some, please?" while signing the psychedelics order with podcaster Joe Rogan and former Navy SEAL Marcus Luttrell present, it illustrated a stunning transformation in what's politically possible—something unimaginable just a decade ago.

Meanwhile, bipartisan support for cannabis reform is mounting in Congress even as implementation remains patchy. Senators Rand Paul, Amy Klobuchar, and Joni Ernst filed a bill allowing states and Indian tribes to opt out of a federal hemp THC product ban scheduled for November, while Senator Cory Booker made headlines by declaring cannabis safer than McDonald's french fries, joking that lawmakers should "schedule McDonald's french fries" instead of cannabis. 🤔 THINK ABOUT IT Alcohol kills approximately 95,000 Americans annually, prescription opioids kill over 16,000 per year, and cannabis has zero recorded overdose deaths in human history—yet cannabis remains Schedule I while alcohol sits perfectly legal on convenience store shelves nationwide.

💰 MONEY MOVES Massachusetts Governor Maura Healey signed comprehensive cannabis reform into law that expands the industry's financial viability by doubling retail licenses businesses can hold from three to six, raising legal possession limits from one to two ounces, and allowing medical marijuana businesses to source cannabis rather than grow it themselves. The changes aim to address "record-low prices and dispensary closures" by letting operators spread overhead costs across more locations. The reformed Cannabis Control Commission will shrink from five members to three, with the governor now appointing all members instead of power being split with the treasurer and attorney general.

State-level resistance remains significant despite national momentum. Tennessee lawmakers voted to block potential medical marijuana legalization following federal rescheduling, illustrating how even as federal policy shifts, individual states are moving in opposite directions. Florida's voters demonstrated public appetite for change—Amendment 3 garnered 55.9 percent support in 2024—yet failed to meet the 60 percent threshold required for passage, leaving recreational use illegal while medical marijuana remains available for qualifying conditions including cancer, epilepsy, PTSD, chronic pain, and others.

The political moment reflects a genuine normalization happening across both parties, with lawmakers from Senator Lindsey Graham to California Governor Gavin Newsom to rapper Nicki Minaj praising Trump's psychedelics order. Louisiana is launching a psychedelic-assisted therapy pilot program using opioid settlement dollars. A growing body of research shows cannabis as a substitute for prescription drugs, and emerging evidence suggests cannabis legalization spurs medical innovation—though not always in directions that benefit public health without scrutiny. 🤔 THINK ABOUT IT With zero overdose deaths, genuine therapeutic applications, and bipartisan political support, the question isn't whether normalization will continue, but how quickly state legislatures and federal agencies will catch up to what voters and scientists already understand.

April 20, 2026

Delaware lawmakers unanimously advanced a bill this week that would allow terminally ill patients to use medical cannabis in hospitals, marking another incremental shift toward normalizing cannabis as a legitimate therapeutic option within institutional healthcare settings. The House of Representatives approved the measure 38-0 on Thursday, following the Senate's unanimous passage about a month earlier. The bill now heads to Governor Matt Meyer (D), who can sign it into law. Rep. Kamela Smith, who carried the legislation, framed it as a patient safety issue: "Patients shouldn't have to choose between following their doctor's treatment plan and following the hospital's rules and protocols."

The Delaware measure reflects a broader recognition among healthcare providers that patients are already using cannabis for cancer, chronic pain, and serious illness—often in secret because existing policies force them to hide medication from their care teams. Under the bill, patients and caregivers would be responsible for acquiring and administering the drug, which would need to be stored securely in locked containers. Smoking and vaping would be prohibited, requiring patients to use edibles or other consumption methods. Healthcare facilities would need to document use in medical records and develop written policies, though they could still prohibit cannabis if they determined it would adversely impact a patient's care.

🚀 THIS IS COOL This hospital-based access framework represents a meaningful step forward: it treats cannabis the same way institutions handle other patient medications—openly, documented, and integrated into the care plan—rather than forcing patients into a position where they must choose between their autonomy and institutional compliance. The safeguards protect both patients and facilities while acknowledging a clinical reality that prohibition was simply masking, not preventing.

Meanwhile, national data reveals the broader impact legalization is having on enforcement. A new report from the Marijuana Policy Project, released Monday on 4/20, shows that annual cannabis arrests in the U.S. have plummeted from a peak of over 870,000 in 2007 to 211,104 in 2025. 💰 MONEY MOVES The 24 states with legal cannabis have made 222,261 fewer arrests in 2025 than the year before legalization—a massive shift in criminal justice resources. But the numbers also show persistent inequality: legalization states made 22,357 cannabis arrests last year, while prohibition states made 186,581 arrests despite having a smaller population. "That is still an alarmingly high number," said MPP executive director Adam Smith, "with each of those arrests representing an actual person whose current reality and future prospects may well be derailed by a criminal record."

🤔 THINK ABOUT IT In 24 states, cannabis is legal and regulated. In the other half of the country, hundreds of thousands of people are still being arrested every year for the same plant. The only difference is geography—and the consequence is a criminal record that can derail housing, employment, and education. The report makes clear that while legalization is working as expected (arrests drop when the legal market replaces the illegal one), prohibition states are still running a criminal justice operation on a substance that is now legal and regulated in nearly half the country. The data speaks for itself: legalization reduces arrests. Prohibition doesn't stop use—it just creates criminals.

April 20, 2026

Federal regulators and Congress are moving aggressively toward restricting hemp-derived THC products, responding to mounting pressure from states and the legal marijuana industry concerned about unregulated intoxicating products flooding their markets. The push represents a significant regulatory shift after years of the hemp industry operating in a gray zone created by the 2018 Farm Bill, which legalized hemp but left THC potency limits ambiguous. Multiple congressional proposals now aim to close what federal officials call the "hemp THC loophole"—the practice of producing hemp-derived delta-8 and delta-10 THC products that skirt traditional marijuana regulations by extracting intoxicating compounds from federally legal hemp rather than regulated cannabis plants. The Missouri Times and other outlets report the Federal Government is preparing restrictions that could fundamentally reshape a sector that didn't exist five years ago.

💰 MONEY MOVES Congressional hemp restrictions threaten an estimated $28 billion industry, according to CNBC, with companies across the sector scrambling to understand what a federal ban would mean for their operations. The crackdown reflects a curious economic tension: state-legal cannabis businesses, which operate in carefully regulated markets with testing, taxation, and licensing requirements, view unregulated hemp-derived THC as unfair competition that undercuts their pricing power and brand legitimacy. Federal restrictions could actually benefit established cannabis retailers who currently compete against cheaper, unregulated hemp products sold in gas stations and online. At the same time, small hemp farmers and retailers—many of whom built businesses in good faith under existing federal law—face potential overnight obsolescence if Congress acts without transition periods or alternative pathways.

Minnesota's regulatory framework has emerged as a potential model for federal action, according to the Star Tribune, suggesting that rather than a total ban, policymakers are exploring the possibility of bringing hemp-derived THC under the same testing, potency, and labeling standards that govern state-legal cannabis. This approach would preserve the agricultural hemp industry while eliminating the intoxicating products that have proliferated since 2018. However, the distinction matters significantly for different stakeholder groups: established cannabis businesses want restrictions to restore market order, while hemp farmers worry about losing a profitable crop, and consumers currently using these products—including veterans managing PTSD and chronic pain through legal THC alternatives—face questions about access and continuity.

The timing is significant. Reports span from November 2025 through March 2026, indicating sustained congressional momentum rather than a passing proposal. 🚀 THIS IS COOL The Minnesota model shows that comprehensive regulation doesn't require outright prohibition—it demonstrates that cannabis and hemp-derived THC can coexist within a framework that protects consumers through testing and transparency while respecting the agricultural and commercial interests involved. That approach contrasts sharply with federal scheduling language and suggests policymakers are thinking beyond prohibition toward actual consumer protection standards.

🤔 THINK ABOUT IT The federal government spent decades enforcing cannabis prohibition while alcohol—which kills roughly 95,000 Americans annually and is the leading drug-related killer of teenagers—remained legal and tax-subsidized. Now, as states build regulated cannabis markets and hemp-derived THC emerges as a legal alternative, federal action targets the zero-overdose-death product rather than addressing documented harms from legal substances. The hemp ban watch is really a story about which industries get to operate in gray zones, and which ones face regulatory pressure—regardless of the actual safety data.

April 20, 2026

# THC in Science: Clinical Trials Begin as Evidence Gap Widens

Researchers across major medical institutions are launching clinical trials to answer a question that's surprisingly unresolved despite decades of cannabis legalization: does THC actually work as medicine? UCHealth and other academic centers are running structured studies on marijuana's therapeutic effects, but they're starting from a position of scientific uncertainty that should concern anyone expecting clear answers anytime soon. A major review published by The New York Times found little evidence of benefit for most medical cannabis applications, while Newswise reported that evidence is lacking for cannabis in most conditions—a stark reminder that legalization has outpaced rigorous clinical validation.

The disconnect between public perception and scientific reality is stark. Medical marijuana is now legal in 38 U.S. states, yet the foundational science remains thin. Britannica's comprehensive analysis of medical cannabis highlighted the ongoing debate around CBD and THC applications, acknowledging both the pros and cons while noting that much of what patients believe about cannabis medicine is built on anecdotal evidence rather than randomized controlled trials. 🚀 THIS IS COOL ScienceDaily's investigation into what cannabis actually does for chronic pain represents the kind of targeted research that's beginning to fill the evidence gap—researchers are moving beyond broad claims to study specific conditions with measurable outcomes.

💰 MONEY MOVES The mismatch between cannabis hype and evidence has real consequences for the market. SciTechDaily reported that "medical cannabis hype hits a wall" as researchers reveal big evidence gaps, suggesting that investor enthusiasm and consumer spending are running ahead of actual proof of efficacy. Patients are spending billions on products that may or may not work as advertised, while pharmaceutical companies watch cannabis edge into territory they've dominated for years. The pressure to legitimize cannabis medicine is real—but rushing approval without solid data would repeat mistakes made with prescription opioids, which killed over 16,000 Americans in recent years.

The clinical trial push represents a turning point. UCHealth's work and similar efforts at major research institutions suggest the cannabis industry is beginning to accept what legitimate medicine requires: reproducible results, control groups, and peer review. 🤔 THINK ABOUT IT We have zero recorded overdose deaths from cannabis in human history, yet Schedule I classification—originally imposed by Nixon in 1970 despite his own Shafer Commission recommending decriminalization—has persisted for over 50 years. Meanwhile, alcohol kills roughly 95,000 Americans annually and remains legal and readily available. If the concern is public health and evidence-based policy, shouldn't the substance with documented harm face stricter scrutiny than the one with none?

What these trials ultimately reveal will matter more than the hype surrounding them. Whether THC proves effective for chronic pain, PTSD, nausea, or other conditions will determine whether medical cannabis becomes a legitimate therapeutic tool or remains a wellness product masquerading as medicine. For now, the science is catching up to the market—and researchers are asking hard questions that should have been answered decades ago.

April 20, 2026

# Texas Cannabis Polling Shows Growing Support as National Arrest Trends Shift Dramatically

A new poll from Texas reveals expanding public appetite for cannabis reform in the state, arriving as national data shows a historic collapse in marijuana arrests across legalization jurisdictions. The Marijuana Policy Project's latest analysis, released Monday on the unofficial cannabis holiday 4/20, documents that annual cannabis arrests in the United States have plummeted from a peak of over 870,000 in 2007 to 211,104 in 2025—a staggering 76 percent decline driven almost entirely by state legalization laws now in effect across 24 jurisdictions.

💰 MONEY MOVES The numbers reveal a widening economic and enforcement gap between legalization and prohibition states. In 2025 alone, legalization states made 22,357 cannabis arrests compared to 186,581 in prohibition states—meaning states that still criminalize cannabis make more than eight times as many arrests despite having smaller total populations. The 24 legalization states collectively made 222,261 fewer cannabis arrests in 2025 than in the year before they legalized, suggesting that legal markets successfully redirect demand away from criminal supply chains. Meanwhile, states like Texas that maintain prohibition continue funneling hundreds of thousands of citizens through the criminal justice system annually for activity now legal in nearly half the country.

🚀 THIS IS COOL The policy shift extends beyond possession enforcement. MPP's analysis found that legalization states saw possession arrests drop by an average of 84.61 percent and sales arrests decrease by an average of 80.39 percent—evidence that regulated markets genuinely displace illegal ones. Adam Smith, MPP's executive director, noted that while the nationwide arrest figure of 211,104 represents "a historic decline," it remains "alarmingly high," with each arrest carrying the potential to derail someone's employment, housing, and educational prospects permanently. Texas polling data showing growing public support for reform suggests voters increasingly recognize this mismatch between cannabis's safety profile and its legal status.

Delaware lawmakers, meanwhile, advanced a more targeted reform this month. The state House passed a bill unanimously (38-0) on Thursday that would allow terminally ill patients to use medical cannabis in hospitals, sending it to Governor Matt Meyer. The measure permits patients and caregivers to acquire and administer medical marijuana on hospital premises under strict safeguards—including secure storage requirements and a prohibition on smoking or vaping. Rep. Kamela Smith, who carried the legislation, framed it as a patient safety measure: "Patients are already using it, especially for cancer, chronic pain and serious illness. Patients shouldn't have to choose between following their doctor's treatment plan and following the hospital's rules and protocols."

🤔 THINK ABOUT IT Cannabis remains Schedule I at the federal level—classified as having no accepted medical use and a high potential for abuse—yet it causes zero recorded overdose deaths in human history. Alcohol kills roughly 95,000 Americans annually, and prescription opioids kill over 16,000 per year. So why does a substance with zero overdose deaths occupy the same legal tier as heroin, while products that kill tens of thousands remain legal? Texas voters increasingly seem to be asking that exact question. As legalization states continue demonstrating that regulated markets work, prohibition states face mounting political and public health pressure to explain why they're sustaining mass arrest rates for something their neighbors have already normalized.